Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rani Therapeutics Holdings (RANI) Equity Average (2021 - 2025)

Rani Therapeutics Holdings (RANI) has 5 years of Equity Average data on record, last reported at -$10.6 million in Q3 2025.

  • For Q3 2025, Equity Average fell 286.54% year-over-year to -$10.6 million; the TTM value through Sep 2025 reached -$10.6 million, down 286.54%, while the annual FY2024 figure was $14.5 million, 70.9% down from the prior year.
  • Equity Average reached -$10.6 million in Q3 2025 per RANI's latest filing, down from -$7.3 million in the prior quarter.
  • Across five years, Equity Average topped out at $126.6 million in Q4 2021 and bottomed at -$121.1 million in Q2 2021.
  • Average Equity Average over 5 years is $26.5 million, with a median of $20.0 million recorded in 2024.
  • Peak YoY movement for Equity Average: surged 2205.96% in 2022, then crashed 286.54% in 2025.
  • A 5-year view of Equity Average shows it stood at $126.6 million in 2021, then crashed by 36.59% to $80.3 million in 2022, then crashed by 62.48% to $30.1 million in 2023, then tumbled by 84.62% to $4.6 million in 2024, then tumbled by 327.95% to -$10.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were -$10.6 million in Q3 2025, -$7.3 million in Q2 2025, and -$928000.0 in Q1 2025.